Administering cryoprecipitate in obstetric bleeding at an earlier time

Not Applicable

Completed

• Conditions: Postpartum haemorrhage; Pregnancy and Childbirth

• Registration Number: ISRCTN12146519
• Lead Sponsor: Queen Mary University of London

Brief Summary

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32565469/ protocol (added 06/01/2021) 2021 Results article in https://doi.org/10.1111/anae.15595 (added 11/11/2021) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/35508349/ qualitative interview findings on deferred consent (added 05/05/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-14
• Study Completion: 2020-04-10
• Last Update Posted: 16 May 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

Pregnant women at >24 weeks gestation, who are actively bleeding within 24 hours of delivery, and for whom at least one unit of RBC has been started or transfused to stem active bleeding

Exclusion Criteria

1. Women who decline blood transfusion in advance
2. Women with inherited Factor XIII
3. Women with inherited fibrinogen deficiency

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of women who were administered cryoprecipitate within 90 minutes of major haemorrhage protocol (MHP) activation, or request of the first unit of RBC transfusion (whichever is earlier)